Since CNS progression is a common site of relapse in NSCLC ALK/ROS1 mutation patients, lorlatinib was developed as a selective brain-penetrant ALK/ROS1 TKI active against most known resistance mutations. This evidence concerns the gene ALK and non-small cell lung carcinoma.